A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer.

MLA

Naohiro Okano, et al. “A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Patients with Borderline-Resectable Pancreatic Cancer.” Internal Medicine, vol. 62, no. 3, Feb. 2023, pp. 327–34. EBSCOhost, https://doi.org/10.2169/internalmedicine.9504-22.

APA

Naohiro Okano, Ryota Matsuki, Masao Toki, Koichi Gondo, Kazushige Ochiai, Shunsuke Watanabe, Hidekatsu Tateishi, Masaharu Kogure, Yutaka Suzuki, Masanori Sugiyama, Fumio Nagashima, Junji Shibahara, Yoshihiro Sakamoto, & Junji Furuse. (2023). A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Internal Medicine, 62(3), 327–334. https://doi.org/10.2169/internalmedicine.9504-22

Chicago

Naohiro Okano, Ryota Matsuki, Masao Toki, Koichi Gondo, Kazushige Ochiai, Shunsuke Watanabe, Hidekatsu Tateishi, et al. 2023. “A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Patients with Borderline-Resectable Pancreatic Cancer.” Internal Medicine 62 (3): 327–34. doi:10.2169/internalmedicine.9504-22.